Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €14.90 EUR
Change Today 0.00 / 0.00%
Volume 993.0
ALIPS On Other Exchanges
EN Paris
As of 9:30 AM 04/27/15 All times are local (Market data is delayed by at least 15 minutes).

qiagen marseille sa (ALIPS) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/17/15 - €14.90
52 Week Low
08/8/14 - €12.91
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for QIAGEN MARSEILLE SA (ALIPS)

Related News

No related news articles were found.

qiagen marseille sa (ALIPS) Related Businessweek News

No Related Businessweek News Found

qiagen marseille sa (ALIPS) Details

QIAGEN Marseille S.A., a molecular diagnosis company, develops and markets diagnostic tests for the oncology field worldwide. The company offers diagnostic kits and biomarkers, as well as is developing diagnostic tools targeting other cancers. Its tests are used in the diagnosis, prognosis, and monitoring of patients with leukemia. The company was formerly known as IPSOGEN S.A. and changed its name to QIAGEN Marseille S.A. in January 2013. The company was founded in 1999 and is headquartered in Marseille, France. As of July 13, 2011, QIAGEN Marseille S.A. operates as a subsidiary of Qiagen N.V.

74 Employees
Last Reported Date: 02/27/15
Founded in 1999

qiagen marseille sa (ALIPS) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

qiagen marseille sa (ALIPS) Key Developments

Qiagen Marseille Société Anonyme, Annual General Meeting, Mar 16, 2015

Qiagen Marseille Société Anonyme, Annual General Meeting, Mar 16, 2015., at 11:00 Central European Standard Time.

QIAGEN Marseille Reports Earnings Results for the First Half Ended June 30, 2014

QIAGEN Marseille reported earnings results for the first half ended June 30, 2014. For the first half, the company reported revenue of EUR 8,252,000 compared to revenue of EUR 7,624,000 for the same period a year ago. Operating income was EUR 8,643,000 compared to EUR 7,971,000 last year. Income from operating activities was EUR 3,387,000 compared to EUR 5,818,000 last year. Net income was EUR 2,797,000 compared to EUR 5,618,000 last year.

QIAGEN Marseille Reports Sales Results for the First Six Months Ended June 30, 2014

QIAGEN Marseille reported sales results for the first six months ended June 30, 2014. For the six months, the company reported total revenue of EUR 8.3 million compared with EUR 7.6 million in the first six months of 2013, an increase of 8% over the same period in 2013.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALIPS:FP €14.90 EUR 0.00

ALIPS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ALIPS.
View Industry Companies

Industry Analysis


Industry Average

Valuation ALIPS Industry Range
Price/Earnings 11.9x
Price/Sales 3.9x
Price/Book 2.5x
Price/Cash Flow 11.9x
TEV/Sales 3.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact QIAGEN MARSEILLE SA, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at